High-profile coronavirus retractions raise concerns about data oversight

High-profile coronavirus retractions raise concerns about data oversight
Source: Nature



Two weeks after a high-profile paper in The Lancet1 reported that the antimalarial drug hydroxychloroquine might be dangerous to patients with COVID-19, three of its four authors have retracted the work because they were unable to independently verify their data set, a large proprietary collection of electronic health records analysed by Surgisphere, a US company.

On the same day, 4 June, the researchers and other co-authors retracted a paper in the New England Journal of Medicine (NEJM)2, for the same reason. That study, published a month ago, had looked at the impact of certain heart medications on people with COVID-19, and found no safety concerns.

Scientists say the affair raises serious questions about the way researchers and journals evaluate the data underlying papers that they publish, and may complicate the effort to trial drugs during the coronavirus pandemic.



Cont'd.

LINK:
https://www.nature.com/articles/d41586-020-01695-w

Discusiones sobre el mismo tema

URL de retroenlace : https://www.ictal.org/index.php?trackback/2041

Fuente de los comentarios de esta entrada